Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.72 USD
+0.02 (3.00%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $0.72 0.00 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.72 USD
+0.02 (3.00%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $0.72 0.00 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Biopharma (CUE) delivered earnings and revenue surprises of 31.03% and 137.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 8.11% and 37.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -5.45% and 18.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 13.11% and 4.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks
by Zacks Equity Research
Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -50% and 13.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
by Zacks Equity Research
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?
by Zacks Equity Research
Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.
Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -9.68% and 3.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -37.50% and 11.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Universal Health (UHS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Universal Health Services' (UHS) first-quarter results are likely to reflect the benefits of increased admissions.
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?
by Zacks Equity Research
Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.